Kotzampasi Danai Maria, Papadourakis Michail, Burke John E, Cournia Zoe
Biomedical Research Foundation, Academy of Athens, Athens 11527, Greece.
Department of Biology, University of Crete, Heraklion 71500, Greece.
Comput Struct Biotechnol J. 2024 Jul 8;23:3118-3131. doi: 10.1016/j.csbj.2024.07.010. eCollection 2024 Dec.
The gene , encoding the catalytic subunit p110α of PI3Kα, is the second most frequently mutated gene in cancer, with the highest frequency oncogenic mutants occurring in the C-terminus of the kinase domain. The C-terminus has a dual function in regulating the kinase, playing a putative auto-inhibitory role for kinase activity and being absolutely essential for binding to the cell membrane. However, the molecular mechanisms by which these C-terminal oncogenic mutations cause PI3Kα overactivation remain unclear. To understand how a spectrum of C-terminal mutations of PI3Kα alter kinase activity compared to the WT, we perform unbiased and biased Molecular Dynamics simulations of several C-terminal mutants and report the free energy landscapes for the C-terminal "closed-to-open" transition in the WT, H1047R, G1049R, M1043L and N1068KLKR mutants. Results are consistent with HDX-MS experimental data and provide a molecular explanation why H1047R and G1049R reorient the C-terminus with a different mechanism compared to the WT and M1043L and N1068KLKR mutants. Moreover, we show that in the H1047R mutant, the cavity, where the allosteric ligands STX-478 and RLY-2608 bind, is more accessible contrary to the WT. This study provides insights into the molecular mechanisms underlying activation of oncogenic PI3Kα by C-terminal mutations and represents a valuable resource for continued efforts in the development of mutant selective inhibitors as therapeutics.
编码PI3Kα催化亚基p110α的基因是癌症中第二常见的突变基因,激酶结构域C末端出现致癌突变体的频率最高。C末端在调节激酶方面具有双重功能,对激酶活性起假定的自抑制作用,并且对于与细胞膜结合绝对必要。然而,这些C末端致癌突变导致PI3Kα过度激活的分子机制仍不清楚。为了了解与野生型相比,PI3Kα的一系列C末端突变如何改变激酶活性,我们对几个C末端突变体进行了无偏和有偏的分子动力学模拟,并报告了野生型、H1047R、G1049R、M1043L和N1068KLKR突变体中C末端“从关闭到开放”转变的自由能景观。结果与氢氘交换质谱(HDX-MS)实验数据一致,并提供了一种分子解释,即为什么与野生型、M1043L和N1068KLKR突变体相比,H1047R和G1049R以不同的机制重新定向C末端。此外,我们表明,在H1047R突变体中,变构配体STX-478和RLY-2608结合的腔与野生型相反,更容易接近。这项研究深入了解了C末端突变激活致癌PI3Kα的分子机制,并为继续开发突变体选择性抑制剂作为治疗药物提供了宝贵的资源。